<DOC>
	<DOCNO>NCT00742495</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics , pharmacodynamics safety different dose intravenous oral Forodesine child relapse refractory T-cell B-cell precursor Acute Lymphoblastic Leukaemia T-cell Non-Hodgkin 's Lymphoma . Preliminary efficacy also assess .</brief_summary>
	<brief_title>Pharmacokinetic Study Forodesine Children With Relapsed Refractory T-cell B-cell Precursor Acute Lymphoblastic Leukaemia T-cell Non- Hodgkin 's Lymphoma .</brief_title>
	<detailed_description>A multi-centre , multi-national , open label trial Forodesine child relapse refractory T-cell B-cell precursor Acute Lymphoblastic Leukaemia T-cell Non-Hodgkin 's Lymphoma . The primary objective study evaluate pharmacokinetics pharmacodynamics six different dose schedule Forodesine . Secondary objective evaluate safety collect preliminary efficacy data . All patient receive active drug . The Initial Treatment Phase last 37 day final response assessment Day 37 . Patients achieve response may eligible receive extend treatment Forodesine 6 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Males female age ≥ 2 year ≤18 year . ≥ 13 kg Female subject childbearing potential ( i.e . reach age menarche ) must negative serum urine pregnancy test record prior first dose study medication , nonlactating , willing use adequate highly effective method contraception throughout study one month last dose study medication , sexually active . Sexually active male subject must willing able use barrier form contraception ( i.e . condom ) sexual abstinence throughout study one month last dose study medication Unequivocal histological diagnosis TALL , BCPALL TNHL ( World Health Organisation [ WHO ] classification ) initial diagnosis Relapse ( ³25 % marrow blast ) failure respond least one standard regimen disease subject Tcell malignancy ineligible therapy great curative potential , failure respond least two standard regimen subject Bcell precursor malignancy KPS LPS ( appropriate subject 's age ) score ³60 Anticipated life expectancy least 6 week Adequate kidney ( creatinine level ≤ 2.0 time upper limit normal ) liver function test ( aspartate aminotransferase [ AST ] and/or alanine aminotransferase [ ALT ] ≤3 time upper limit normal total bilirubin ≤5 time upper limit normal ) Signed ICF assent appropriate accord local law regulation prior start study specific procedure . Exclusion criterion : Females pregnant ( positive βhCG test ) lactate Subjects history HIV and/or HTLV1 Subjects know active HBV , HCV , CMV and/or EBV infection Subjects clinical evidence active symptomatic CNS disease Subjects active serious infection Prior treatment antileukemic agent , chemotherapy leukophoresis treatment within 7 day ( within 45 day 6mercaptopurine ( MP ) within 2 day lowdose methotrexate ) prior study entry Lack full recovery adverse drug reaction due prior therapy , independent therapy give Concurrent treatment anticancer agent ( CNS prophylaxis e.g . intrathecal methotrexate corticosteroid use exclude ) Subjects chronic gastrointestinal disease condition may hamper compliance and/or absorption product ; however , study drug administration via nasogastric gastrostomy tube allow Any history hypersensitivity intolerance component study medication . Subjects received investigational medicinal product within 30 day study entry ( defined start Screening Period ) . Current participation another clinical trial permit unless sole purpose trial long term follow up/survival data .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>